Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma - PubMed (original) (raw)

Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma

S F Shariat et al. Cancer. 2001.

Abstract

Background: Elevated local and circulating levels of transforming growth factor (TGF)-beta(1) have been associated with cancer invasion, progression, and metastasis. The authors tested the hypothesis that preoperative plasma TGF-beta(1) levels would independently predict cancer stage and prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.

Methods: The study group consisted of 51 patients who underwent radical cystectomy for muscle-invasive or intravesical immuno- and/or chemotherapy refractory Tis, Ta, or T1 TCC (median follow-up, 45.7 months). Preoperative plasma levels of TGF-beta(1) were measured and correlated with pathologic features and clinical outcome. Transforming growth factor-beta(1) levels also were measured in 44 healthy men without any cancer.

Results: The mean preoperative plasma TGF-beta(1) level in patients who eventually developed metastases to distant (11.9 +/- 0.9 ng/mL) or regional (9.6 +/- 2.4 ng/mL) lymph nodes was significantly higher than that in patients with nonmetastatic muscle-invasive TCC (5.4 +/- 1.1 ng/mL), which, in turn, was significantly higher than that in patients with nonmetastatic Tis, Ta, or T1 TCC (4.5 +/- 1.2 ng/mL) and healthy subjects (4.5 +/- 1.2 ng/mL; P < 0.001). Preoperative plasma TGF-beta(1) level was an independent predictor of lymphovascular invasion (P = 0.002), metastases to lymph nodes (P = 0.030), disease recurrence (P = 0.009), and disease specific survival (P = 0.015). In a subgroup of patients with muscle-invasive TCC, TGF-beta(1) level was associated with disease recurrence (P = 0.005) and death from bladder carcinoma (P = 0.001).

Conclusions: The authors confirm that plasma TGF-beta(1) levels are elevated in patients with muscle-invasive TCC before cystectomy. Transforming growth factor-beta(1) levels are highest in patients with bladder carcinoma metastatic to lymph nodes and are a strong independent predictor of disease recurrence and disease specific mortality.

PubMed Disclaimer

Cited by

TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation.
Chen Z, He S, Zhan Y, He A, Fang D, Gong Y, Li X, Zhou L. Chen Z, et al. EBioMedicine. 2019 Sep;47:208-220. doi: 10.1016/j.ebiom.2019.08.012. Epub 2019 Aug 13. EBioMedicine. 2019. PMID: 31420300 Free PMC article.
Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1_H_-imidazoles as ALK5 inhibitors.
Park MS, Park HJ, An YJ, Choi JH, Cha G, Lee HJ, Park SJ, Dewang PM, Kim DK. Park MS, et al. J Enzyme Inhib Med Chem. 2020 Dec;35(1):702-712. doi: 10.1080/14756366.2020.1734799. J Enzyme Inhib Med Chem. 2020. PMID: 32164459 Free PMC article.
Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGFβ-1.
Kerr BA, Harris KS, Shi L, Willey JS, Soto-Pantoja DR, Byzova TV. Kerr BA, et al. Am J Clin Exp Urol. 2021 Feb 15;9(1):18-31. eCollection 2021. Am J Clin Exp Urol. 2021. PMID: 33816691 Free PMC article.
Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D. Javle M, et al. PLoS One. 2014 Jan 20;9(1):e85942. doi: 10.1371/journal.pone.0085942. eCollection 2014. PLoS One. 2014. PMID: 24465802 Free PMC article.
Circulating Biomarkers in Bladder Cancer.
Nandagopal L, Sonpavde G. Nandagopal L, et al. Bladder Cancer. 2016 Oct 27;2(4):369-379. doi: 10.3233/BLC-160075. Bladder Cancer. 2016. PMID: 28035318 Free PMC article. Review.

Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma - PubMed (original) (raw)